Profitelligence Profitelligence · Filing Ledger Open KVUE research →

Form 8-K · Current Report · Filed 2025-07-14

Kenvue Announces CEO Transition and Strategic Review

Kenvue Inc. announced a CEO transition with Thibaut Mongon stepping down and Kirk Perry appointed as interim CEO, effective immediately. The company also announced an ongoing comprehensive review of strategic alternatives to unlock shareholder value. Preliminary Q2 2025 results showed a 4.0% decline in net sales and organic sales down 4.2%. The company will report full Q2 2025 financial results and revise its full-year 2025 outlook on August 7, 2025.

Filer
Kenvue Inc. KVUE · NYSE
Filed
Accession
0000950157-25-000569
CIK
0001944048
Signal
High impactConsumer Defensive

Items reported

Item 2.02

Results of Operations and Financial Condition

General Statement
Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

CEO Resignation New CEO Appointed
Item 8.01

Other Events

Corporate Update
Item 9.01

Financial Statements and Exhibits

No viable tag

Market reaction

Close before filing

$21.34

Next session

+0.2%

Since filing

-9.8%

Latest close

$19.24

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from KVUE reporting the same item, with the next session's move:

Exhibits (2)

About Kenvue Inc.

Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.

Exchange NYSE Industry Household & Personal Products Company website ↗

Never miss another KVUE filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts